How to Read a Peptide Certificate of Analysis (COA): A Practical Guide

Why the COA matters

The Certificate of Analysis is the document that transforms a vial of white powder from "trust the vendor" to "verify what's in the bottle." A legitimate COA is generated from actual analytical testing of a specific batch. It documents whether the peptide is the correct compound (identity), how pure it is (purity), and whether it's contaminated with harmful substances (safety).

The problems: COAs are technical documents most users can't fully interpret, some vendors use formatting that obscures quality issues rather than revealing them, and outright fabrication of COAs has been documented in the research peptide market. This guide walks through what each COA section actually means and what to question.

Section 1: Product identification and batch information

What should be there

• Full product name matching the label on the vial (e.g., "BPC-157 Acetate 5 mg")
• Batch/lot number linking this COA to a specific production run
• Date of manufacture and expiration date
• Date of testing
• Manufacturing site or contract facility identification
• Testing laboratory identification (ideally third-party, not the vendor's in-house lab)

Red flags

• Missing batch number or generic identifier like "recent batch"
• Product name on COA doesn't exactly match the vial label
• No testing date, only a "printed" date
• No manufacturer or testing lab identification
• Same COA used across multiple different-looking batches (indicating COA reuse rather than actual per-batch testing)

Section 2: Peptide identity verification

Mass spectrometry (MS)

What it measures: The actual molecular weight of the peptide, compared to the theoretical molecular weight calculated from the amino acid sequence.

Common methods: ESI-MS (electrospray ionization), MALDI-TOF (matrix-assisted laser desorption/ionization time-of-flight).

What to look for: The observed molecular weight should match the theoretical molecular weight to within a few Daltons. For BPC-157 (theoretical MW = 1419.5 Da), a report showing observed MW = 1419.5 or 1420.6 (with the [M+H]+ ion) is correct. A report showing 1419.5 for a peptide that should be 2932.5 is a serious problem.

Red flags: Missing MS data entirely, MS results that don't match the expected molecular weight, generic "identity confirmed" statement without actual numerical data.

Sequence verification

Higher-quality COAs include amino acid analysis or MS/MS sequence verification confirming the actual amino acid sequence matches the labeled peptide. This is less commonly reported but represents higher standard of verification.

Section 3: Purity assessment

HPLC purity (the primary metric)

What it measures: Percentage of the peptide compound versus impurities and byproducts.

Common method: Reverse-phase HPLC (RP-HPLC), usually reported at UV detection wavelength 220 nm or 254 nm.

What to look for:

• Research-grade peptides: typically ≥95%, better vendors report 98% or 99%
• Pharmaceutical-grade compounds: typically ≥99%
• The HPLC method should specify column, mobile phase, and detection wavelength
• The COA should ideally include the actual chromatogram (peaks visible) rather than just a numerical value

Red flags:

• Purity below 95% for a compound sold for research use
• No HPLC method specification (unable to verify claim)
• Numerical purity value without a chromatogram (harder to verify the claim)
• Vague statements like "high purity" without specific numerical values
• Different purity claims across the vial label, product page, and COA

What the impurities are

The remaining percentage in a "98% pure" peptide isn't necessarily benign material. Common impurities include:

• Truncated peptides (missing amino acids from synthesis errors)
• Deamidation products (aspartate/asparagine conversions)
• Oxidation products (methionine oxidation, cysteine disulfides)
• Residual protecting groups from synthesis
• Acetate or TFA salt (not truly "impurity" but affects actual peptide content, see Section 4)

Section 4: Peptide content (net vs gross weight)

This is the section most users completely miss and where a lot of quality misunderstanding lives.

What "5 mg vial" actually contains

A vial labeled "5 mg BPC-157" doesn't necessarily contain 5 mg of pure BPC-157 peptide. It contains 5 mg of peptide product, which includes the peptide itself, salt (acetate or TFA), water, and any other counterions.

Example: A 5 mg vial of BPC-157 acetate salt at 85% peptide content actually contains 4.25 mg of BPC-157 peptide plus 0.75 mg of acetate salt and water.

What to look for on the COA

• Peptide content (net): Percentage of the vial contents that is actual peptide, typically 80-95% for research peptides
• Salt form: Usually acetate (preferred, low toxicity) or TFA (trifluoroacetic acid, can have concerns at high levels)
• Water content: Typically 3-10% residual water after lyophilization
• The math: Net peptide + salt + water should approximately equal 100%

Why this matters practically

If you're reconstituting a 5 mg vial as 5 mg of peptide but the actual peptide content is 4.25 mg, your actual dosing is 15% less than calculated. Quality vendors either specify the actual peptide content on the COA and label, or overfill vials to deliver the labeled peptide amount.

Section 5: Safety-related tests

Endotoxin (LAL test)

What it measures: Bacterial endotoxin content, particularly important for peptides used via injection.

Method: Limulus Amebocyte Lysate (LAL) assay.

Acceptable ranges: Research-grade peptides intended for injection use should show <0.5 EU/mg (endotoxin units per milligram) or better.

Red flags: No endotoxin testing for products marketed for injection, extremely high detection limits that make "not detected" meaningless.

Bacterial count / bioburden

Total aerobic microbial count and yeast/mold counts. Should be very low or undetectable in properly manufactured peptide products.

Heavy metals

Elements like lead, cadmium, mercury, arsenic. Should be below regulatory acceptance limits. Some vendors don't test for these; better vendors do.

Residual solvents

Peptide synthesis uses organic solvents (DMF, DCM, acetonitrile, methanol) that must be removed. COAs may report residual solvent levels against ICH Q3C guidelines.

Section 6: Appearance and physical properties

• Appearance description: typically "white to off-white powder" for lyophilized peptides
• Solubility notes
• pH of reconstituted solution (if reported)

These are less critical than identity and purity but should be documented.

The independent verification question

The most-often-cited COA red flag is vendor in-house testing versus independent third-party testing.

Vendor in-house COAs

Testing performed by the vendor's own analytical lab. Can be legitimate but has obvious conflict-of-interest issues.

Third-party independent COAs

Testing performed by an independent analytical laboratory unaffiliated with the vendor. Higher trust level because the lab has no incentive to misrepresent results.

What better vendors do

• Publish both the vendor QC COA and an independent third-party verification for the same batch
• Name the independent laboratory (e.g., Janoshik Analytical, various academic testing services)
• Include the third-party COA directly on the product page, beyond "third-party tested" claims
• Update COAs with each new batch rather than reusing the same document

How to actually use this when shopping

Before buying

1. Locate the COA on the product page. If there's no COA available for public review, that's a significant red flag.
2. Check the batch number and date, is this a recent COA?
3. Verify the product name on the COA matches the product page exactly
4. Look for HPLC purity ≥98% for premium claims, ≥95% minimum for standard research grade
5. Look for mass spectrometry confirming identity
6. Check for peptide content (net) if available — this tells you what you're actually getting
7. For injectable use: verify endotoxin testing was performed and results are acceptable
8. Prefer vendors publishing independent third-party verification alongside their internal COA

After receiving product

1. Verify the batch number on the vial label matches the batch number on the COA you received
2. Verify the vial appearance matches the description (white to off-white lyophilized powder)
3. Consider third-party independent testing for higher-value purchases or specifically-important compounds, services like Janoshik Analytical offer independent verification

Common COA red flags, quick reference

• No COA available: Do not buy.
• Generic COA reused across batches: Batch-specific testing not being performed.
• COA doesn't specify batch number: Cannot verify traceability to your vial.
• Purity claim without HPLC method or chromatogram: Unverifiable.
• Missing mass spectrometry identity confirmation: Cannot verify the peptide is what's labeled.
• No endotoxin testing on products marketed for injection: Safety concern.
• Purity below 95% for a "research grade" claim: Below industry standard.
• Only vendor in-house testing, no independent verification: Conflict of interest.
• Batch number on vial doesn't match COA batch number: Wrong batch or COA fraud.
• Different purity claimed on product page vs COA: Marketing overstatement.

The vendor landscape context

The March 2026 DOJ enforcement actions against several research peptide vendors highlighted quality and marketing issues across the industry. See our State of the Peptide Market 2026 for the full context. Quality vendors documented their responses to increased regulatory scrutiny by improving COA transparency and third-party testing.

For vendor evaluation frameworks, see our how to evaluate peptide vendors article. For the emerging Category 2 status framework affecting compounding-pharmacy access, see our FDA PCAC article.

Related content

For deeper coverage of the vendor and regulatory landscape: How to evaluate peptide vendors, State of the Peptide Market 2026, Peptide storage guide, FDA PCAC July 2026 article. For safety context: High-caution peptides, Peptide side effects guide.